Collaboration and License Agreements (Tables)

12 Months Ended

Dec. 31, 2021

Collaboration And License Agreements [Abstract]

Summary of Allocation of Total Transaction Price and Unsatisfied Transaction Price

The following table summarizes the allocation of the total transaction price to the identified performance obligations under the arrangement, and the amount of the transaction price unsatisfied as of December 31, 2021 (in thousands):

	Transaction Price Allocated		Transaction Price Unsatisfied
Performance obligations:
Research and development targets	$	58,628	$	26,996
Option rights		6,694		3,488
Total	$	65,322	$	30,484

Schedule of Revenue from Collaboration Agreements

Revenue from collaboration agreements was as follows (in thousands):

	Years Ended December 31,
	2021		2020		2019
Revenue from collaboration agreements:
Roche Agreement	$	19,379	$	9,051	$	6,409
Biogen Agreement		15,720		9,913		2,432
Calico Agreement		10,686		14,231		12,540
Total revenue from collaboration agreements	$	45,785	$	33,195	$	21,381

Schedule of Financial Information Related to Collaboration and License Agreements

Supplemental information related to the collaboration and license agreements consisted of the following in the Company’s consolidated balance sheet as of December 31, 2021 (in thousands):

	Accounts Receivable		Deferred Revenue, Current		Deferred Revenue, Net of Current		Deferred Revenue, Total
Supplemental information:
Roche Agreement	$	1,215	$	5,601	$	17,215	$	22,816
Biogen Agreement		3,000		24,032		6,611		30,643
Calico Agreement		1,501		2,167		542		2,709
Total	$	5,716	$	31,800	$	24,368	$	56,168

Supplemental information related to the collaboration and license agreements consisted of the following in the Company’s consolidated balance sheet as of December 31, 2020 (in thousands):

	Accounts Receivable		Deferred Revenue, Current		Deferred Revenue, Net of Current		Deferred Revenue, Total
Supplemental information:
Roche Agreement		750		11,238		26,991		38,229
Biogen Agreement		776		13,965		26,026		39,991
Calico Agreement		2,958		2,400		600		3,000
Total	$	4,484	$	27,603	$	53,617	$	81,220

Schedule of Supplemental Financial Information Related to Collaboration and License Agreements

Supplemental financial information related to the collaboration and license agreements are (in thousands):

	Years Ended December 31,
	2021		2020		2019
Revenue recognized that was included in the contract liability at the beginning of the period	$	34,363	$	17,570	$	11,948
Revenue recognized from performance obligations fully or partially satisfied in previous periods		1,654		348		—